Telix Pharmaceuticals is trading at A$15.00 (-4.64%), with no verified new company announcement or clear catalyst identified for the October 19, 2026 move.
- The ITM acquisition was announced September 21 and is prior context, not a confirmed new trigger.
- U.S. futures pointed to risk-off pressure ahead of Monday, but the available evidence does not establish that this caused Telix’s decline.
- Supplied market indices are flat, and no volume information was provided.